Royalty Pharma plc (RPRX)
NMS · Healthcare · Biotechnology
$54.87
-0.76%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$31.34B
P/S (TTM)
12.8x
P/E (TTM)
33.2x
Exchange
NMS
About Royalty Pharma plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 578.7M | 609.3M | 622.0M | 630.6M |
| Operating Income | 209.8M | 427.2M | 388.4M | 632.5M |
| Net Income | 30.2M | 288.2M | 214.2M | 294.7M |
| Diluted EPS | $0.07 | $0.67 | $0.38 | $0.53 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 2.2B | 2.4B | 2.3B | 2.4B |
| Operating Income | 922.9M | 1.5B | 1.3B | 1.6B |
| Net Income | 42.8M | 1.1B | 859.0M | 770.9M |
| Diluted EPS | $0.10 | $2.53 | $1.45 | $1.78 |